236 related articles for article (PubMed ID: 36368473)
1. Factors associated with infection events after chimeric antigen receptor T-cell therapy for relapsed or refractory multiple myeloma.
Zhou D; Wang Y; Cheng H; Zhu L; Chen W; Li H; Zhang X; Xia J; Qi Y; Ma S; Zhu F; Yan Z; Qi K; Sang W; Sun H; Li D; Cao J; Li Z; Xu K
J Infect Chemother; 2023 Feb; 29(2):179-185. PubMed ID: 36368473
[TBL] [Abstract][Full Text] [Related]
2. Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma.
Ma S; Li H; Zhou D; Zhang X; Shi M; Cao J; Qi Y; Xia J; Liu Y; Wang X; Li D; Sang W; Yan Z; Zhu F; Sun H; Cheng H; Zheng J; Xu K; Li Z; Qi K; Wang Y
Cytotherapy; 2023 Jun; 25(6):653-658. PubMed ID: 36907717
[TBL] [Abstract][Full Text] [Related]
3. A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed/refractory multiple myeloma patients treated with CAR-T cells.
Liu Y; Jie X; Nian L; Wang Y; Wang C; Ma J; Jiang J; Wu Q; Qiao J; Chen W; Cao J; Yan Z; Shi M; Cheng H; Zhu F; Sang W; Li D; Chen C; Xu K; Li Z
Front Immunol; 2023; 14():1169071. PubMed ID: 37153543
[TBL] [Abstract][Full Text] [Related]
4. Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy.
Zhang M; Zhou L; Zhao H; Zhang Y; Wei G; Hong R; Wu W; Xu H; Wang L; Ni F; Cui J; Peng S; Huang CH; Chang AH; Hu Y; Huang H
Clin Cancer Res; 2021 Dec; 27(23):6384-6392. PubMed ID: 34548316
[TBL] [Abstract][Full Text] [Related]
5. Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials.
Que Y; Xu M; Xu Y; Almeida VDF; Zhu L; Wang Z; Wang Y; Liu X; Jiang L; Wang D; Li C; Zhou J
Front Immunol; 2021; 12():755866. PubMed ID: 34777368
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of single infusion of anti-BCMA versus combined infusion of anti-CD19 chimeric antigen receptor T cells for immune reconstruction in relapsed/refractory multiple myeloma].
Ge J; Zhao TT; Wan CY; Xia JY; Guo SY; Yu MX; Chen J; Wang Y; Xu KL; Li ZY
Zhonghua Xue Ye Xue Za Zhi; 2021 Sep; 42(9):733-738. PubMed ID: 34753227
[No Abstract] [Full Text] [Related]
7. A phase I study of anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia.
Li C; Cao W; Que Y; Wang Q; Xiao Y; Gu C; Wang D; Wang J; Jiang L; Xu H; Xu J; Zhou X; Hong Z; Wang N; Huang L; Zhang S; Chen L; Mao X; Xiao M; Zhang W; Meng L; Cao Y; Zhang T; Li J; Zhou J
Clin Transl Med; 2021 Mar; 11(3):e346. PubMed ID: 33784005
[TBL] [Abstract][Full Text] [Related]
8. High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma.
Tang Y; Yin H; Zhao X; Jin D; Liang Y; Xiong T; Li L; Tang W; Zhang J; Liu M; Yu Z; Liu H; Zang S; Huang Z
J Exp Clin Cancer Res; 2022 Jan; 41(1):2. PubMed ID: 34980210
[TBL] [Abstract][Full Text] [Related]
9. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.
Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W
Front Immunol; 2021; 12():755549. PubMed ID: 34777367
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma.
Zhang L; Shen X; Yu W; Li J; Zhang J; Zhang R; Li J; Chen L
Ann Med; 2021 Dec; 53(1):1547-1559. PubMed ID: 34459681
[TBL] [Abstract][Full Text] [Related]
11. [The characteristics and impact on prognosis of cytopenia after anti-BCMA-CAR-T therapy in patients with relapsed and refractory multiple myeloma].
Shen XX; Yao Y; Xia Y; Jin YY; Zhang R; Li JY; Chen LJ
Zhonghua Yi Xue Za Zhi; 2024 Feb; 104(7):507-513. PubMed ID: 38317362
[No Abstract] [Full Text] [Related]
12. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.
Raje N; Berdeja J; Lin Y; Siegel D; Jagannath S; Madduri D; Liedtke M; Rosenblatt J; Maus MV; Turka A; Lam LP; Morgan RA; Friedman K; Massaro M; Wang J; Russotti G; Yang Z; Campbell T; Hege K; Petrocca F; Quigley MT; Munshi N; Kochenderfer JN
N Engl J Med; 2019 May; 380(18):1726-1737. PubMed ID: 31042825
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease.
Deng H; Liu M; Yuan T; Zhang H; Cui R; Li J; Yuan J; Wang X; Wang Y; Deng Q
Front Immunol; 2021; 12():720571. PubMed ID: 34421924
[TBL] [Abstract][Full Text] [Related]
14. [Observation of liver indexes in patients with relapsed/refractory multiple myeloma treated with CAR-T-cells based on BCMA].
Sun Q; Qi YK; Qi KM; Yan ZL; Cheng H; Chen W; Zhu F; Sang W; Li DP; Cao J; Shi M; Li ZY; Xu KL
Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):832-837. PubMed ID: 38049335
[No Abstract] [Full Text] [Related]
15. Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma.
Banerjee R; Marsal J; Huang CY; Lo M; Kambhampati S; Kennedy VE; Arora S; Wolf JL; Martin TG; Wong SW; Shah N
Transplant Cell Ther; 2021 Jun; 27(6):477.e1-477.e7. PubMed ID: 33831353
[TBL] [Abstract][Full Text] [Related]
16. Risk factors of tumor lysis syndrome in relapsed/refractory multiple myeloma patients undergoing BCMA CAR-T cell therapy.
Zhang Q; Zu C; Meng Y; Lyu Y; Hu Y; Huang H
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):144-150. PubMed ID: 36161293
[TBL] [Abstract][Full Text] [Related]
17. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.
Yan Z; Cao J; Cheng H; Qiao J; Zhang H; Wang Y; Shi M; Lan J; Fei X; Jin L; Jing G; Sang W; Zhu F; Chen W; Wu Q; Yao Y; Wang G; Zhao J; Zheng J; Li Z; Xu K
Lancet Haematol; 2019 Oct; 6(10):e521-e529. PubMed ID: 31378662
[TBL] [Abstract][Full Text] [Related]
18. Pathogen-Specific Humoral Immunity and Infections in B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy Recipients with Multiple Myeloma.
Josyula S; Pont MJ; Dasgupta S; Song X; Thomas S; Pepper G; Keane-Candib J; Stevens-Ayers TL; Ochs HD; Boeckh MJ; Riddell SR; Cowan AJ; Krantz EM; Green DJ; Hill JA
Transplant Cell Ther; 2022 Jun; 28(6):304.e1-304.e9. PubMed ID: 35288345
[TBL] [Abstract][Full Text] [Related]
19. Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed/refractory multiple myeloma: a case report and revies of the literature.
Zhao G; Wei R; Feng L; Wu Y; He F; Xiao M; Cheng Z
Cancer Immunol Immunother; 2022 Jan; 71(1):39-44. PubMed ID: 34003300
[TBL] [Abstract][Full Text] [Related]
20. Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial.
Shi M; Wang J; Huang H; Liu D; Cheng H; Wang X; Chen W; Yan Z; Sang W; Qi K; Li D; Zhu F; Li Z; Qiao J; Wu Q; Zeng L; Fei X; Gu W; Miao Y; Xu K; Zheng J; Cao J
Nat Commun; 2024 Apr; 15(1):3371. PubMed ID: 38643278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
